Optimized And Scalable LNP Composition For RNA Vaccine Delivery

GettyImages-1409578453-mRNA-LNP-lipid-nanoparticle-RNA therapy

Lipid nanoparticle-encapsulated RNA (RNA-LNP) vaccines have been instrumental in the global response to the COVID-19 pandemic and are currently at various stages of clinical development for different infectious diseases. In this field, limited access to potent ionizable lipids and the expertise needed to optimize scalable formulations pose significant barriers to entry. To overcome these challenges, Precision NanoSystems developed a novel ionizable lipid along with a corresponding LNP composition. This formulation is optimized for vaccine delivery and scalable from bench to clinic.

Explore results from a study screening novel LNP formulations for physicochemical attributes, in vitro potency, and in vivo immunogenicity in both SARS-CoV-2 and influenza vaccine applications. Discover the storage stability and scalability of the lead LNP candidate as well as how this formulation can fast-track and de-risk drug development timelines.

access the Poster!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene